August 27, 2014 3:30 PM ET


Company Overview of Rivanna Pharmaceuticals Inc.

Executive Profile

Mark A. Cochran Ph.D.

Chairman and Interim Chief Executive Officer, Rivanna Pharmaceuticals Inc.
AgeTotal Calculated CompensationThis person is connected to 6 Board Members in 6 different organizations across 9 different industries.

See Board Relationships


Dr. Mark A. Cochran, Ph.D. serves as the Chief Executive Officer at Klarogen Biotherapeutics, Inc. Dr. Cochran serves as an Interim Chief Executive Officer at Rivanna Pharmaceuticals Inc. since 2005 and serves as its Chairman. Dr. Cochran served as the Chief Business Officer and Director of Microbix Biosystems, Inc. He has an extensive background in life sciences that includes roles in research, drug development, business development, and venture capital. He served as ...

Corporate Headquarters

325 Barracks Hill
Charlottesville, Virginia 22901

United States

Phone: 434-973-0177
Fax: --

Board Members Memberships

Former Director
Former Board Observer
Chairman and Interim Chief Executive Officer


University of Toronto
Master's Degree
University Of Guelph
Queen's University

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Rivanna Pharmaceuticals Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at